Pfizer (NYSE:PFE) Issues FY 2024 Earnings Guidance

Pfizer (NYSE:PFE) updated its FY 2024 earnings guidance on Tuesday. The company provided EPS guidance of 2.450-2.650 for the period, compared to the consensus EPS estimate of 2.380. The company issued revenue guidance of $59.5 billion-$62.5 billion, compared to the consensus revenue estimate of $60.7 billion.

Pfizer Stock Performance

PFE traded down $0.45 during trading hours on Wednesday, hitting $30.94. 20,024,121 shares of the stock were exchanged, compared to its average volume of 39,950,676. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78. The stock has a market cap of $175.32 billion, a price-to-earnings ratio of -516.58, a price-to-earnings-growth ratio of 1.20 and a beta of 0.69. Pfizer has a 12 month low of $25.20 and a 12 month high of $37.19. The stock has a 50-day simple moving average of $28.64 and a 200-day simple moving average of $27.79.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The firm had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. During the same period in the previous year, the company earned $0.67 earnings per share. Pfizer’s revenue was up 2.1% compared to the same quarter last year. Analysts anticipate that Pfizer will post 2.38 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be given a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 5.43%. The ex-dividend date of this dividend is Friday, July 26th. Pfizer’s dividend payout ratio is currently -2,799.53%.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on PFE shares. Morgan Stanley raised their target price on Pfizer from $28.00 to $29.00 and gave the company an equal weight rating in a research note on Thursday, May 2nd. Wells Fargo & Company lifted their target price on Pfizer from $28.00 to $30.00 and gave the company an equal weight rating in a research report on Wednesday. Cantor Fitzgerald reaffirmed an overweight rating and set a $45.00 price target on shares of Pfizer in a research report on Wednesday. Barclays lifted their target price on Pfizer from $28.00 to $30.00 and gave the stock an equal weight rating in a research note on Wednesday, July 10th. Finally, BMO Capital Markets restated an outperform rating and issued a $36.00 price target (up from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Nine research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, Pfizer currently has an average rating of Hold and a consensus target price of $34.42.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.